Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
Jeffrey S Heier,Eleonora M Lad,Frank G Holz,Philip J Rosenfeld,Robyn H Guymer,David Boyer,Federico Grossi,Caroline R Baumal,Jean-Francois Korobelnik,Jason S Slakter,Nadia K Waheed,Ravi Metlapally,Ian Pearce,Nathan Steinle,Anibal A Francone,Allen Hu,David R Lally,Pascal Deschatelets,Cedric Francois,Caleb Bliss,Giovanni Staurenghi,Jordi Monés,Rishi P Singh,Ramiro Ribeiro,Charles C Wykoff,Abosede O Cole,Adam T Gerstenblith,Ajay Kotagiri,Albert O Edwards,Alberto D Zambrano,Alexander M Eaton,Alexander Rubowitz,Alice T Lyon,Allen Chiang,Allen Ho,Allen Y Hu,Amir H Guerami,Amr L Dessouki,André Corrêa Maia de Carvalho,Andrés Emanuelli,Andrew A Chang,Andrew N Antoszyk,Anibal Andrés Francone,Anita Prasad,Armin Wolf,Arshad M Khanani,Ashkan Michael Abbey,Asma Moulana,Barbara Wihelm,Bartosz L Sikorski,Baruch D Kuppermann,Benjamin Wolff,Brian H Jewart,Brian K Do,Brian T Chan-Kai,Calvin Mein,Carel B Hoyng,Carl C Awh,Carl Regillio,Carlos Zeolite,Caroline R Baumal,Catherine Creuzot-Garcher,Catherine Français Maury,Charles C Wykoff,Charles K Newell,Chirag Jhaveri,Chris P Lohmann,Christiana B Dinah,Colin Ma,Courtney Crawford,D Wilkin Parke,Daniel Lavinsky,Daniel Roth,Dante J Pieramici,Darius M Moshfeghi,Darrin Levin,David A Saperstein,David Brown,David Gaucher,David R Lally,David S Liao,David Warren Brown,Debra Goldstein,Dennis Marcus,Derek G Chan,Dilsher Dhoot,Domingo Tacite,Dominik Zalewski,Edgar M Espana,Eleonora M Lad,Eric H Souied,Eric P Suan,Eva Eting,Federico Furno Sola,Flore de Bats,Francesco Bandello,Francisco Gómez-Ulla,François Devin,Frank G Holz,Fred K Chen,Fuad Makkouk,Gawain Dyer,George Spital,Giovanni Staurenghi,Glenn Stoller,Gwen Cousins,Hani Salehi-Had,Hansjürgen Agostini,Haralabos Eleftheriadis,Harold Weiss,Harris C Sultan,Hélène Massé,Ian Pearce,Indra Dias,Irene Barbazetto,Irit Rosenblatt,Ivan J Suñer,Jaclyn L Kovach,Jakub Kaluzny,James Borthwick,James G Howard,James Wong,Jan Ernest,Jan Němčanský,Jason Edward Ysasaga,Jason M Handza,Javier Antonio Montero Moreno,Jean-François Korobelnik,Jeffrey S Heier,Jennifer J Arnold,Jeremiah Brown,Joaquin Bafalluy,Joel Pearlman,John D Pitcher,John Kitchens,John P Carlson,Jolly Gilhotra,Jordana Fein,Jordi M Monés,José Domingo Luna,José María Ruiz Moreno,Joseph M Coney,Juliana Maria Ferraz Sallum,Karl R Olsen,Katharina Blobner,Katherine A Macoul,Kean T Oh,Khurram Javed Malik,Lars-Olof Hattenbach,Laurent Kodjikian,Laurentino Biccas Neto,Lawrence J Singerman,Lebriz Altay,Leo-H Sheck,Leonard Feiner,Lindsey D Harris,Lionel D Chishold,Llewelyn J Rao,Márcio Bittar Nehemy,Maria Jose Capella Elizalde,Maria-Andreea Gamulescu,Mario J Saravia,Mark W Johnson,Martin McKibbin,Mathew Maccumber,Matko Vidosevich,Matthew P Ohr,Michael A Samuel,Michael A Singer,Michael Cassell,Michael Dollin,Michael J Elman,Michael S Ip,Michaella Goldstein,Miguel Busquets,Mihai Mititelu,Milan Shah,Miroslav Veith,Mitchell Fineman,Monica Varano,Nancy Christmas,Nathan C Steinle,Nauman Chaudhry,Nicholas D Chinskey,Nicole Eter,Nikolas J S London,Nurit Mathalone,Patricio G Schlottmann,Patrick Coady,Patrick M Higgins,Paul A Raskauskas,Paul A Yates,Paul Bernstein,Paul Mitchell,Paul Monsour,Paul V Raphaelian,Paulo E Stanga,Pavel Stodulka,Peter Charbel Issa,Peter Pavan,Phil J Ferrone,Piotr Oleksy,Prema Abraham,Prithvi Mruthyunjaya,Quan Dong Nguyen,Rahul K Reddy,Rahul N Khurana,Raman Tuli,Ramin Tadayoni,Randy Steven Katz,Rashi Arora,Reinier O Schlingemann,Richard B Rosen,Richard Gale,Richard Scartozzi,Ricky Isernharge,Rishi P Singh,Robert A Stoltz,Robert L Avery,Robert S Wirthlin,Robyn Guymer,Roger A Goldberg,Ronald Frenkel,Rubens Jr Belfort,Saddek Mohand-Said,Salvatore Grisanti,Sam Razavi,Samantha Fraser-Bell,Sandeep N Shah,Sanjeewa Wickremasinghe,Sara Joy Haug,Sean D Adrean,Siegfried G Priglinger,Simona Degli Esposti,Stephen Guest,Stephen Huddleston,Sujit Itty,Suk Jin Moon,Sumit P Bhatia,Sunil Gupta,Sunil S Patel,Sunir J Garg,Sunir Joshi,Sylvia Nghiem-Buffet,T Mark Johnson,Tareq Jaouni,Thomas Ach,Thomas R Williams,Thomas Sheidow,Timothy P Cleland,Timothy T You,Tunde Peto,Vasileios Konidaris,Victor H Gonzalez,Vladimir Korda,William R Freeman,William Z Bridges,Yoreh Barak,Zbigniew Zagorski,Zohar Yehoshua,Zora Dubska
DOI: https://doi.org/10.1016/s0140-6736(23)01520-9
IF: 202.731
2023-10-01
The Lancet
Abstract:Background Geographic atrophy is a leading cause of progressive, irreversible vision loss. The objectives of OAKS and DERBY were to assess the efficacy and safety of pegcetacoplan compared with sham treatment in patients with geographic atrophy. Methods OAKS and DERBY were two 24-month, multicentre, randomised, double-masked, sham-controlled, phase 3 studies, in which patients aged 60 years and older with geographic atrophy secondary to age-related macular degeneration were enrolled at 110 clinical sites and 122 clinical sites worldwide, respectively. Patients were randomly assigned (2:2:1:1) by central web-based randomisation system to intravitreal 15 mg per 0·1 mL pegcetacoplan monthly or every other month, or sham monthly or every other month using stratified permuted block randomisation (stratified by geographic atrophy lesion area at screening, history or presence of active choroidal neovascularisation in the eye not under assessment, and block size of six). Study site staff, patients, reading centre personnel, evaluating physicians, and the funder were masked to group assignment. Sham groups were pooled for the analyses. The primary endpoint was the change from baseline to month 12 in the total area of geographic atrophy lesions in the study eye based on fundus autofluorescence imaging, in the modified intention-to-treat population (ie, all patients who received one or more injections of pegcetacoplan or sham and had a baseline and at least one post-baseline value of lesion area). Key secondary endpoints (measured at 24 months) were change in monocular maximum reading speed of the study eye, change from baseline in mean functional reading independence index score, change from baseline in normal luminance best-corrected visual acuity score, and change from baseline in the mean threshold sensitivity of all points in the study eye by mesopic microperimetry (OAKS only). Safety analyses included patients who were randomly assigned and received at least one injection of pegcetacoplan or sham. The now completed studies are registered with ClinicalTrials.gov, NCT03525613 (OAKS) and NCT03525600 (DERBY). Findings Between Aug 30, 2018, and July 3, 2020, 1258 patients were enrolled in OAKS and DERBY. The modified intention-to-treat populations comprised 614 (96%) of 637 patients in OAKS (202 receiving pegcetacoplan monthly, 205 pegcetacoplan every other month, and 207 sham) and 597 (96%) of 621 patients in DERBY (201 receiving pegcetacoplan monthly, 201 pegcetacoplan every other month, and 195 sham). In OAKS, pegcetacoplan monthly and pegcetacoplan every other month significantly slowed geographic atrophy lesion growth by 21% (absolute difference in least-squares mean –0·41 mm2, 95% CI –0·64 to –0·18; p=0·0004) and 16% (–0·32 mm2, –0·54 to –0·09; p=0·0055), respectively, compared with sham at 12 months. In DERBY, pegcetacoplan monthly and pegcetacoplan every other month slowed geographic atrophy lesion growth, although it did not reach significance, by 12% (–0·23 mm2, –0·47 to 0·01; p=0·062) and 11% (–0·21 mm2, –0·44 to 0·03; p=0·085), respectively, compared with sham at 12 months. At 24 months, pegcetacoplan monthly and pegcetacoplan every other month slowed geographic atrophy lesion growth by 22% (–0·90 mm2, –1·30 to –0·50; p<0·0001) and 18% (–0·74 mm2, –1·13 to –0·36; p=0·0002) in OAKS, and by 19% (–0·75 mm2, –1·15 to –0·34; p=0·0004) and 16% (–0·63 mm2, –1·05 to –0·22; p=0·0030) in DERBY, respectively, compared with sham. There were no differences in key secondary visual function endpoints at 24 months. Serious ocular treatment-emergent adverse events were reported in five (2%) of 213, four (2%) of 212, and one (<1%) of 211 patients in OAKS, and in four (2%) of 206, two (1%) of 208, and two (1%) of 206 patients in DERBY receiving pegcetacoplan monthly, pegcetacoplan every other month, and sham, respectively, at 24 months. New-onset exudative age-related macular degeneration was reported in 24 (11%), 16 (8%), and four (2%) patients in OAKS, and in 27 (13%), 12 (6%), and nine (4%) patients in DERBY receiving pegcetacoplan monthly, pegcetacoplan every other month, and sham, respectively, at 24 months. Interpretation Pegcetacoplan, the first treatment approved by the US Food and Drug Administration for geographic atrophy, slowed geographic atrophy lesion growth with an acceptable safety profile. Funding Apellis Pharmaceuticals.
medicine, general & internal